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Abstract: Hypertension is a major risk factor for the development of cardiovascular and renal 
disease. The incidence of hypertension is increasing globally and the rate of blood pressure 
control remains inadequate. Renin-angiotensin-aldosterone system (RAAS) plays a crucial 
role in volume regulation and maintenance of blood pressure. Pathological activation of 
RAAS results in chronic hypertension and consequent end organ damage. Most patients with 
hypertension require combination therapy using agents with complimentary mechanisms of 
action. Hydrochlorothiazide (HCTZ) together with an agent blocking the RAAS such as an 
angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) are 
widely used effective anti-hypertensive therapy. Aliskiren is an orally effective direct renin 
inhibitor that blocks the generation of angiotensin I from angiotensinogen, the rate limiting step 
of RAAS activation. Studies have shown equivalent antihypertensive efﬁ  cacy of aliskiren when 
compared to existing medications such as HCTZ, ACE inhibitors and ARBs. Aliskiren has also 
been tested in combination therapies. The current review aims to look at the efﬁ  cacy of aliskiren 
therapy in hypertension and the evidence for using aliskiren in combination with HCTZ.
Keywords: hypertension, renin-angiotensin-aldosterone system, aliskiren, aliskiren-
hydrochlorothiazide, combination therapy, renin inhibitors
Introduction
Elevated blood pressure (BP) is a major risk factor for the development of myocardial 
infarction, heart failure, stroke and renal failure. Greater than 25% of the global 
population was hypertensive in 2000 with a 60% projected increase in incidence 
by the year 2025 (Kearney et al 2005). Approximately 30% of the US population is 
hypertensive (Ong et al 2007). According to the 7th Joint National Committee on 
the prevention, detection, evaluation and treatment of high blood pressure (JNC-7), 
only about a third of treated US adult patients have their BP adequately controlled 
(Chobanian et al 2003). An epidemiology study of hypertension treatment and control 
in ﬁ  ve European countries, Canada and the US showed lower treatment and control 
rates in Europe when compared to North America (Wolf-Maier et al 2004).
Hypertension is a treatable disease and effective medical therapies have been 
available for nearly 5 decades. Socio-economic conditions, treatment non-compliance 
and inadequate prevention strategies have all been implicated as barriers to adequate BP 
control. The major pharmacological strategies currently utilized for hypertension 
management include volume control with diuretics, suppression of central and 
peripheral sympathetic nervous system activity, vasodilation with ion channel manipu-
lation and blockade of renin-angiotensin-aldosterone system (RAAS). Monotherapy 
results in adequate control of BP only in fewer that 50% of patients (Materson et al 
1993; Cushman et al 2002; Chobanian et al 2003). Most patients require combination Vascular Health and Risk Management 2008:4(6) 1206
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therapy using agents with complimentary mechanisms of 
action. Life style modiﬁ  cation should also be an integral part 
of the treatment plan. Combination therapy may enable the 
utilization of sub-maximal doses of component drugs thus 
minimizing adverse events without signiﬁ  cantly affecting 
potency. Several combination agents are currently avail-
able. The most widely used combinations involve a thiazide 
diuretic like hydrochlorothiazide (HCTZ) together with a 
drug blocking the RAAS such as angiotensin converting 
enzyme (ACE) inhibitor or angiotensin receptor blocker 
(ARB). RAAS has long been known to play a crucial role in 
both the regulation of BP as well as atherogenesis and vas-
cular damage (Oparil and Haber 1974; Dzau 2001). Thiazide 
diuretics block the uptake of Na+ in the distal convoluted 
tubule of the nephron resulting in salt and water depletion. 
While this can lower the BP, the resulting activation of the 
RAAS may limit the antihypertensive beneﬁ  ts of diuretics. 
Thus drugs that inhibit the RAAS such as ACE inhibitors and 
ARBs are considered attractive for combination with thiazide 
diuretics (Skolnik et al 2000; Waeber B 2003). Recently, 
a direct renin inhibitor namely aliskiren was approved by 
the US Food and Drug Administration and the European 
regulatory agency for the treatment of hypertension. The 
antihypertensive efﬁ  cacy of aliskiren has been studied both as 
monotherapy and in combination with other agents including 
HCTZ. The current review includes an overview of RAAS 
and the clinical experience of renin blockade with aliskiren in 
hypertension with particular focus on the evidence for using 
aliskiren/HCTZ combination. Articles published in English 
language pertaining to aliskiren were reviewed.
Renin-angiotensin-aldosterone 
system and its blockade
A schematic of the RAAS is depicted in Figure 1. Renin 
is an aspartic protease generated and released from the 
juxtaglomerular cells in the kidney. The renin molecule 
has two homologous lobes and the cleft between the lobes 
contain the active site (Danser and Deinum 2005). Under 
the inﬂ  uence of renin, angiotensinogen, the only know 
substrate of renin is cleaved to generate the decapeptide 
angiotensin I (Ang I). This is the rate-limiting step of RAAS 
activation. In the presence of angiotensin converting enzyme 
(ACE), Ang I is converted into the octapeptide hormone 
angiotensin II (Ang II), a powerful vasoconstrictor that 
mediates its activity through the type-1 angiotensin II (AT1) 
receptor. Binding of Ang II to AT1 receptor increases BP, and 
promotes aldosterone secretion from adrenal cortex, sodium 
reabsorption in renal proximal tubules, and catecholamine 
release from pre-synaptic nerve endings and adrenal medulla 
(Kim and Iwao 2000). Pathological activation of RAAS can 
result in hypertension with consequent end-organ damage.
Several medications can interrupt the RAAS cascade 
but redundant pathways limit drug effects. Beta blockers 
inhibit renin secretion from the juxtaglomerular cells. 
ACE inhibitors block the conversion of Ang I to Ang II but 
non-ACE pathways of Ang II generation such as chymase 
and dipeptidases present in end organs including heart, 
kidney and blood vessels get activated under condi-
tions of ACE inhibition (Hollenberg et al 1998; Urata 
et al 1990). ACE inhibitors are not speciﬁ  c for RAAS 
and can prevent ACE-induced inactivation of bradykinin 
and substance P that are thought to be responsible for 
ACE-inhibitor related side effects such as cough and 
angioedema. ARBs exert their effect by blocking AT1 
receptors activation by Ang II. This may lead to unopposed 
stimulation of other types of receptors such as type-2 and 
type-4 Ang II receptors (AT2 and AT4 receptors). Physi-
ological role of these receptors are not clear but may be 
important for endothelial function (Wantanabe et al 2005). 
Over stimulation of AT2 receptors can generate deleteri-
ous agents such as oxygen free radicals, pro-inﬂ  ammatory 
cytokines and pro-ﬁ  brotic mediators and may promote 
left ventricular hypertrophy (Williams 2001; Azizi et al 
2006). On the other hand, beneﬁ  cial effects such as inhi-
bition of renin synthesis and Ang II formation are also 
reported following AT2 receptor activation (Siragy et al 
2005). Both ACE inhibitors and ARBs stimulate renal 
renin production by disrupting the inhibitory feed back of 
Ang II on juxtaglomerular cells. The resulting increase in 
renin eventually restores Ang II level.
As mentioned before, the rate limiting step in RAAS 
is the conversion of angiotensinogen to Ang I under 
the inﬂ  uence of renin. There is a steep step down in 
concentration from angiotensinogen to Ang I which 
makes renin inhibition an attractive option for effective 
RAAS blockade. Animal studies using gene-dosing strate-
gies showed increase in BP in the presence of increased 
copies of angiotensinogen gene but not with ACE gene, 
underscoring the rationale for blocking the conversion of 
angiotensinogen to Ang I (Smithies 1997). Even though 
renin was discovered more than a century ago, a success-
ful direct renin inhibitor has been available for clinical 
use only recently. Investigational renin inhibitors such as 
remikiren, enalkiren, ditekiren and zanikern developed 
in the past were limited by short half-life, high costs, 
and poor bioavailability (Fisher and Hollenberg 2001). Vascular Health and Risk Management 2008:4(6) 1207
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Aliskiren is the ﬁ  rst direct renin inhibitor with sufﬁ  cient 
bioavailability (2.5%), safety and efﬁ  cacy that was tested 
in human studies.
Pro-renin is an inactive precursor of renin that is 
constitutively released from the kidney. Pro-renin is rendered 
inactive by a 43-amino acid N-terminus that covers the 
enzymatic cleft. The circulating level of pro-renin is approxi-
mately 10-fold higher than renin levels and the proportion 
is increased in diabetics (Luetscher et al 1985; Danser et al 
1998). Increased pro-renin levels may predict the onset of 
microalbuminuria in patients with diabetes (Chiarelli et al 
2001). Pro-renin can undergo proteolytic and nonproteolytic 
activation. Proteolytic activation occurs predominantly in 
the juxtaglomerular cells. Nonproteolytic activation can be 
induced by exposure to low temperature and low pH as well 
as through binding to the recently discovered (pro)renin 
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Figure 1 Renin-angiotensin-aldosterone system and the sites of blockade.   Thick arrows indicate main pathways, thin arrows denote alternative pathways and dashed arrows 
show sites of blockade.
Abbreviations: ACE, angiotensin converting enzyme;   ARB, angiotensin receptor blocker;   AT-R, angiotensin receptor;  DRI, direct renin inhibitor;  LVH, left ventricular hypertrophy.Vascular Health and Risk Management 2008:4(6) 1208
Sureshkumar
receptor (Nguyen et al 2002). (Pro)renin receptors have 
been localized to mesangial cells, distal collecting tubular 
cells of kidney, vascular smooth muscle cells, human heart 
and brain. These receptors bind both renin and pro-renin. 
Once bound to (pro)renin receptors, activated pro-renin and 
renin facilitate circulation independent Ang I production 
locally. The binding also promote intracellular signaling 
pathways in an angiotensin independent manner through 
mitogen-activated protein kinases leading to upregulation 
of pro-ﬁ  brotic mediators with harmful end-organ conse-
quences that are inhibited by neither ACE inhibitors nor 
ARBs. (Pro)renin receptor blockade inhibited progression 
of nephropathy and reversed glomerulosclerosis in rats 
with streptozotozin- induced diabetes with proteinuria and 
glomerulosclerosis (Takahashi et al 2007).
Aliskiren: pharmacokinetic 
and pharmacodynamic properties
Aliskiren is a small-molecular-weight, orally active, 
non-peptide direct renin inhibitor with very high afﬁ  nity 
and speciﬁ  city for human renin (Wood et al 2003). It blinds 
to the S1/S3 pocket at the active site of renin molecule 
thus preventing the conversion of angiotensinogen to 
Ang I. Aliskiren is a potent inhibitor of renin with an IC50 
(concentration inhibiting 50% of activity) of 0.6 nmol/L. 
Renin is measured as plasma renin concentration (PRC) 
and plasma renin activity (PRA). PRC measures the actual 
amount of renin in plasma regardless of its enzymatic 
activity and is expressed as either μU/mL or pg/mL. PRA 
denotes the enzymatic activity of renin and is measured as 
the rate of angiotensin I production after adding serum to 
angiotensinogen. PRA is expressed as ng/ml/hour.
Effects of various medications on RAAS pathway are 
shown in Table 1. With the exception of beta blockers, all 
other agents blocking RAAS and diuretics including HCTZ 
increase PRC. Aliskiren and ACE inhibitors achieve this by 
decreasing Ang II levels and ARBs by blocking inhibitory 
effects of Ang II on AT 1 receptors on juxtaglomerular 
cells. Diuretics increase PRC by inducing volume deple-
tion. The magnitude of PRC elevation is more pronounced 
when aliskiren is combined with HCTZ. PRA is increased by 
ACE inhibitors, ARBs and HCTZ while aliskiren use alone 
and in combination with HCTZ is associated with a decrease 
in PRA. Other agents that can decrease PRA include beta 
blockers and centralα-2 receptor agonists.
Pharmacokinetic properties
Pharmacokinetic properties of aliskiren have been reported 
before (Azizi et al 2006; Novartis Pharmaceuticals Corporation 
2007; Waldmeier et al 2007). After an oral dose, the 
bioavailability of aliskiren is 2.5%. High aqueous solubility 
and affinity for renin compensates for the low absolute 
bioavailability of aliskiren. Peak plasma concentration is 
achieved within one to three hours following a single oral dose. 
Plasma concentration increased in a dose dependent manner 
at dose ranges of 40 to 640 mg/day. Steady state blood levels 
are reached in about 7 to 8 days. A terminal half-life of 23 to 
36 hours makes the drug suitable for once daily administration 
(Azizi et al 2006). A dose-dependent increase in trough plasma 
concentration of aliskiren from 2.6 to 30.0 ng/mL was seen 
with aliskiren doses ranging from 37.5 to 300 mg/day in one 
study (Stanton et al 2003). Mean trough plasma concentra-
tions of aliskiren were 10.7 ± 6.7, 13.1 ± 8.3, 9.5 ± 5.9 and 
7.6 ± 3.2 ng/mL respectively in hypertensive patients taking 
aliskiren 150 mg, aliskiren/HCTZ 150/25 mg, ramipril/
aliskiren 5/150 mg and irbesartan aliskiren 150/150 mg daily 
in another study (O’Brien et al 2006).
Aliskiren has a large volume of distribution and a plasma 
protein binding of 49.5%. Mean area under the curve (AUC) 
and Cmax of aliskiren decreased by 71% and 85% respectively 
when taken with a high fat meal (Novartis Pharmaceuticals 
Corporation 2007). Patients should take aliskiren on an 
Table 1 Medication effects on RAAS pathway
Medication PRC PRA Angiotensinogen Ang I Ang II Ang 1–7 Aldosterone
β-Blocker ↓↓− ↓ ↓ ↓ ↓
ACE-I ↑↑↓ ↑ ↓ ↑ ↓
ARB ↑↑↓ ↑ ↑ ↑ ↓
Aliskiren ↑↑ ↓↓ − ↓ ↓ ↓ ↓
HCTZ ↑↑↓ ↑ ↑ ↑ ↑
Aliskiren/HCTZ combination ↑↑↑ ↓ − − − − −
Abbreviations: ACE-I, angiotensin converting enzyme inhibitor;   Ang I, angiotensin I;   Ang II, angiotensin II;   Ang 1–7, angiotensin 1–7;   ARB, angiotensin receptor blocker;  HCTZ, 
hydrochlorothiazide;  PRA, plasma renin activity;  PRC, plasma renin concentration; ↑, increased;  ↓, decreased; −, unchanged or unknown.Vascular Health and Risk Management 2008:4(6) 1209
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empty stomach and establish a routine pattern with regard 
to meals. A 32% to 70% inter-subject variability in AUC 
and Cmax was noted for a 40 to 1800 mg dose range of oral 
aliskiren (Nussberger et al 2002). AUC and Cmax were higher 
by 28% and 57% respectively in subjects over 65 years 
compared to those 18 to 45 years old (Vaidyanathan et al 
2007). Following the administration of 300 mg aliskiren in 
healthy subjects, 90.9% drug elimination was via the fecal 
route and only 0.6% was recovered from urine (Waldmeier 
et al 2007). Hepatic ﬁ  rst-pass effect is minimal for aliskiren 
and modiﬁ  cation of starting dose is not recommended in 
patients with hepatic and renal impairment. Pharmacokinetics 
of aliskiren are similar among Japanese, Blacks and 
Caucasians.
Aliskiren is not metabolized by cytochrome P450 system 
and has a low potential for drug interactions. The pharmaco-
kinetics of amlodipine, valsartan, HCTZ and ramipril were 
not inﬂ  uenced by co-administration with aliskiren in healthy 
volunteers (Vaidyanathan et al 2006). Co-administration 
of lovastatin, atenolol, celecoxib and cimetidine did not 
signiﬁ  cantly change AUC and therapeutic half-life of aliski-
ren (Dieterle et al 2005). Aliskiren did not exert detectable 
effects on the pharmacokinetics and pharmacodynamics of 
warfarin (Dieterle et al 2004). There were no clinically sig-
niﬁ  cant interactions between aliskiren and digoxin in health 
volunteers (Dieterich et al 2006). Co-administration of aliski-
ren with furosemide reduced the AUC and Cmax of furosemide 
by 30% and 50% respectively (Novartis Pharmaceuticals 
Corporation 2007).
Pharmacodynamic properties
Since renin is very species speciﬁ  c, animal testing of human 
renin inhibitors are limited to marmosets and guinea pigs. 
Aliskiren doses of 1 and 3 mg/kg completely suppressed 
PRA for 6 and 12 hours respectively in sodium depleted mar-
mosets (Wood et al 2005). BP lowering effects of aliskiren 
were similar to valsartan and benzapril. Aliskiren decreased 
PRA, Ang I and Ang II levels in normotensive volunteers 
in a dose dependent manner but caused a 10-fold increase 
in PRC (Nussberger et al 2002). A decrease in plasma and 
urine aldosterone levels were also noted with daily aliskiren 
doses of 80 mg and above. Aliskiren 160 mg and enalapril 
20 mg doses were comparable in terms of their inhibitory 
effects on Ang II levels (Nussberger et al 2002).
A small randomized four-period cross-over study looked 
at the effects of single doses of aliskiren 300 mg, valsartan 
160 mg and aliskiren/valsartan 150/80 mg combination in 
12 mildly sodium-depleted volunteers (Azizi et al 2004). 
Aliskiren lowered PRA, and plasma levels of Ang I and 
Ang II for 48 hours, stimulated active renin release more 
strongly than valsartan 160 mg and decreased urinary 
aldosterone excretion for longer duration than valsartan 
160 mg. The effects of aliskiren/valsartan 150/80 mg were 
similar to aliskiren 300 mg but greater than those of valsartan 
160 mg. Aliskiren blunted the valsartan-induced rise in PRA 
and plasma levels of Ang I and Ang II. Similar ﬁ  ndings were 
also reported in sodium-replete normotensive individuals 
(Azizi et al 2007).
Preclinical target organ protection 
studies of aliskiren
Since renin is highly species speciﬁ  c and aliskiren inhibits 
only primate renin, usual animal models of hypertension 
studies can not be used to test the end organ effects of 
aliskiren. Double transgenic rats (dTGR) which carries 
human genes for both renin and angiotensin were developed 
to circumvent this issue (Ganten et al 1992; Fukamizu et al 
1993). These dTGR can generate large amounts of Ang II and 
untreated animals die by 8 weeks from cardiac dysfunction 
and renal failure. This feature makes dTGR an excellent 
model to test the effects of human renin inhibitors.
The target organ protection by aliskiren and valsartan 
were compared in dTGR (Pilz et al 2005). Matched dTGR 
received no treatment, aliskiren (0.3 or 3 mg/kg/day) or 
valsartan (1 or 10 mg/kg/day) from weeks 6 to 9. All 
groups had hypertension at week 6. Untreated dTGR devel-
oped worsening hypertension, increased creatinine and 
albuminuria by week 7 with 100% mortality by week 9. Both 
aliskiren treated groups and high-dose valsartan treated group 
had lower BP and albuminuria and normal serum creatinine 
levels by weeks 9 with 100% survival. Mortality was 26% in 
low-dose valsartan group and this group also had ventricular 
hypertrophy and diastolic dysfunction. In this model, renin 
inhibition had more favorable effect on end organ damage 
compared to angiotensin receptor blockade. In another 
study of dTGR model, both aliskiren and losartan reduced 
albuminuria and renal expression of inﬂ  ammatory markers 
(Shagdarsuren et al 2005). Similar ﬁ  ndings with reduction 
of albuminuria and reduced gene expression of TGF-beta 
and collagen III and IV were observed with aliskiren use in 
dTGR with diabetic nephropathy (Kelly et al 2007).
The role of renin inhibition and AT1-receptor blockade in 
attenuating cardiac oxidative stress and cellular remodeling 
was evaluated in the transgenic TG(mRen2)27 rat, a rodent 
model of chronically elevated tissue Ang II levels with con-
sequent hypertension, insulin resistance and cardiovascular Vascular Health and Risk Management 2008:4(6) 1210
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damage (Whaley-Connell et al 2008). Administration of 
aliskiren and irbesartan were both associated with signiﬁ  cant 
attenuation of cardiac functional and structural alterations in 
TG (mRen2)27 rats but irbesartan caused greater reductions 
in BP and markers of oxidative stress. In another study, 
aliskiren use lowered BP, prevented albuminuria and sup-
pressed renal expressions of TGF-beta and collagen I in 
streptozotozin-diabetic TG (mRen2)27 rats (Feldman et al 
2008). Aliskiren also reduced renal expression of (pro)renin 
receptor.
Clinical efﬁ  cacy of aliskiren 
in hypertension
Aliskiren has been evaluated as both monotherapy and in 
combination therapy in the treatment of hypertension. Table 2 
outlines the studies of aliskiren in hypertension.
Aliskiren monotherapy in hypertension
Clinical trials have compared the antihypertensive efﬁ  cacy 
of aliskiren with placebo, HCTZ, ARBs, ACE inhibitors and 
calcium channel blockers. The antihypertensive effect of 
aliskiren was evaluated in 455 Japanese patients with a mean 
sitting diastolic BP (msDBP) of 95 to 110 mmHg (Kushiro 
et al 2006). Patients were assigned to aliskiren 75 mg, 150 mg 
or 300 mg or placebo for 8 weeks in a double-blind random-
ized manner. Aliskiren produced a dose dependent-reduction 
in both msDBP (p   0.0005 vs placebo for each dose) and 
mean sitting systolic BP (msSBP) (p   0.001 vs placebo for 
each dose). Placebo corrected reductions in msSBP/ msDBP 
were 5.7/4.0, 5.9/4.5 and 11.2/7.5 mmHg for aliskiren 
doses of 75, 150 and 300 mg respectively. At the study end, 
27.8%, 47.8%, 48.2% and 63.7% of patients in the placebo 
and aliskiren 75, 150 and 300 mg groups, respectively had 
a successful response (deﬁ  ned as a DBP   90 mmHg and/
or  10 mmHg reduction from baseline, p   0.005 vs placebo 
for each aliskiren dose). However it should be noted that only 
about 36% of patients showed adequate response to 300 mg 
aliskiren monotherapy when corrected for the placebo effect. 
Aliskiren demonstrated placebo-like tolerability. In another 
study, 672 patients with msDBP of 95 to 109 mmHg were 
randomized to aliskiren doses of 150 mg, 300 mg, 600 mg 
or placebo for 8 weeks (Oh et al 2007). Compared to a 
reduction in msSBP/msDBP of 3.8/4.9 mmHg with placebo, 
aliskiren doses of 150 mg, 300 mg and 600 mg resulted in 
13.0/10.3, 14.7/11.1 and 15.8/12.5 mmHg reductions respec-
tively (p   0.0001). Aliskiren doses of 150 mg, 300 mg and 
600 mg resulted in PRA reductions of 79.5%, 81.1% and 
75.0% from baseline but PRC increased by 51.5%, 101.6% 
and 228.5% from the baseline. Patients taking 600 mg of 
aliskiren reported increased incidence of diarrhea.
In a multi-center double-blind trial, 652 patients with mild 
to moderate hypertension were randomized to once-daily 
doses of aliskiren (150 mg, 300 mg or 600 mg) irbesartan 
150 mg or placebo for 8 weeks (Gradman et al 2005). 
Compared to placebo, all doses of aliskiren signiﬁ  cantly 
lowered trough msSBP and msDBP (p   0.001) (Table 2). 
The dose-response curve for aliskiren showed a plateau at 
300 mg and antihypertensive efﬁ  cacy was similar between 
aliskiren 150 mg and irbesartan 150 mg. BP control (deﬁ  ned 
as a BP   140/90 mmHg) was achieved in 37.8%, 50% and 
20.8% of patients on aliskiren 150 mg, 300 mg and placebo. 
Aliskiren was well tolerated.
Another double-blind trial randomized 226 patients with 
mild to moderate hypertension to four doses of aliskiren 
(37.5 mg, 75 mg, 150 mg, 300 mg) or losartan 100 mg daily 
for 4 weeks (Stanton et al 2003). The mean ± SD changes 
in daytime ambulatory systolic BP were −0.4 ± 11.7, 
−5.3 ± 11.3, −8.0 ± 11.0 and –11.0 ± 11.0 mmHg respec-
tively in patients receiving 37.5 mg, 75 mg, 150 mg and 
300 mg doses of aliskiren (p = 0.0002). The changes in PRA 
(median change as percentage with inter- quartile range) 
for the same doses of aliskiren were −55 (−64, −11), −60 
(−82, −46), −77 (−86, −72) and −83 (−92, −71) respec-
tively (p = 0.0008). Losartan 100 mg increased the PRA 
by 110%. The change in day time systolic pressure with 
100 mg losartan (−10.9 ± 13.8 mmHg) was not signiﬁ  cantly 
different from the changes seen with 75, 150 and 300 mg 
aliskiren. All doses of aliskiren were well tolerated.
A multicenter 8-week trial randomized 1123 patients 
with mild to moderate hypertension (msDBP   95 mmHg) 
to once daily doses of aliskiren (75 mg, 150 mg or 300 mg), 
valsartan (80 mg, 160 mg or 320 mg), aliskiren/valsartan 
combinations (75/80 mg 150/160 mg or 300/320 mg), 
valsartan/HCTZ (160/12.5 mg) or placebo (Pool et al 2007). 
Compared with placebo, there were signiﬁ  cant reductions in 
both msSBP and msDBP with aliskiren 300 mg (10.0/8.6 vs 
15.0/12.3 mmHg, p   0.001). Valsartan 160 mg and 320 mg 
doses lowered msSBP and msDBP signiﬁ  cantly compared 
to aliskiren 150 mg (p   0.05 for both valsartan doses) 
(Table 2). Placebo effect was prominent. A pooled analysis 
involving 8481 patients involved in double-blind trials with 
aliskiren and placebo arms for a period of 8 to 12 weeks 
revealed reductions in msSBP/ msDBP of 12.5/10.1 and 
15.2/11.8 mmHg respectively from baseline with aliskiren 
150 and 300 mg doses compared to 6.2/5.9 mmHg with 
placebo (p   0.0001) (Dahlof et al 2007).Vascular Health and Risk Management 2008:4(6) 1211
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The efﬁ  cacy, safety and tolerability of aliskiren were 
evaluated in patients   65 years of age (Verdecchia et al 2007). 
In this study, 355 elderly patients with msSBP 145–179 mmHg 
and mean 24-hour ambulatory SBP of   135 mmHg under-
went double-blind randomization to 8-week treatment with 
once daily aliskiren (75, 150 or 300 mg) or lisinopril 10 mg. 
At study end, mean 24-hour ambulatory SBP/DBP decreased 
by 8.4/4.5, 7.1/3.6, 8.7/3.9 and 10.2/ 6.3 mmHg respectively 
with aliskiren 75, 150 and 300 mg and lisinopril 10 mg 
doses. A higher proportion of patients on aliskiren 300 mg 
vs 75 mg achieved BP   140/90 mmHg (36.2% vs 24.2%, 
p = 0.033). All doses of aliskiren were well tolerated. Another 
study randomized 842 patients (msDBP 95–109 mmHg) to 
aliskiren 150 mg or ramipril 5 mg with subsequent doubling 
of the drug doses and addition of HCTZ (12.5–25 mg) for 
inadequate BP control (Andersen et al 2008). At 26-week 
follow-up, aliskiren-based therapy significantly lowered 
msSBP (17.9 vs 15.2 mmHg, p = 0.0036), msDBP (13.2 vs 
12.0 mmHg, p = 0.025) and resulted in higher rates of BP 
control (61.4% vs 53.0%, p = 0.0205) compared to ramipril 
based therapy. During drug withdrawal, BP increased more 
rapidly after stopping ramipril than aliskiren based therapy, 
median BP reached 140/90 mmHg after 1 and 4 weeks of drug 
withdrawal respectively. The incidence of serum potassium 
levels   5.5 mmol/L was 1.9% in the aliskiren group and 
1% in the ramipril group.
A double-blind multi-center 8-week trial randomized 
183 patients with severe hypertension (msDBP 105–119 mmHg) 
in a 2:1 ratio, to aliskiren 150 mg or lisinopril 20 mg with dose-
doubling and subsequent addition of HCTZ for additional BP 
control (Strasser et al 2007). Reductions in msSBP and msDBP 
as well as responder rates (81.55 vs 87.9%) were similar between 
aliskiren and lisinopril groups (Table 2). Half of patients in each 
group needed HCTZ for adequate BP control.
In summary, monotherapy with aliskiren was well 
tolerated with antihypertensive effects comparable to losartan, 
irbesartan, lisinopril and ramipril. Dose-response curve 
seems to plateau at 300 mg of aliskiren. Aliskiren consis-
tently lowered PRA. Prominent placebo effects seen in most 
studies were attributed to factors such as regression to the 
mean, residual effects from previous therapy and limitations 
of cuff BP measurements.
Aliskiren combination therapy 
in hypertension
Antihypertensive efﬁ  cacy, safety and tolerability of aliskiren in 
combination with HCTZ, ACE inhibitors, ARBs and calcium 
channel blockers were tested in patients with hypertension.
Combination with an ACE inhibitor, ARB 
or calcium channel blocker
Dual blockade of the RAAS can be achieved by utilizing 
combination of aliskiren with either an ACE inhibitor or 
an ARB. The additional antihypertensive effects of adding 
6 weeks of aliskiren therapy (75 mg in the ﬁ  rst 3 weeks and 
150 mg in the last 3 weeks) in patients with mild to moderate 
hypertension on monotherapy with ramipril (n = 21) or 
irbesartan (n = 23) was assessed in an open-label design using 
ambulatory blood pressure monitoring (ABPM) (O’Brien et al 
2007). The addition of aliskiren to 5 mg of ramipril further 
lowered both day time and night time BP compared to ramipril 
monotherapy while the addition of aliskiren to 150 mg of 
irbesartan resulted in signiﬁ  cant reduction in night time BP 
(Table 2). Ramipril and irbesartan monotherapy caused 90% 
and 175% increase in PRA respectively. By contrast, when 
aliskiren was co-administered with ramipril or irbesartan, 
PRA levels were similar to or less than baseline values. Treat-
ment compliance assessed from pill counts averaged   95%. 
The maximum individual serum potassium levels recorded 
when aliskiren was co-administered with ramipril or irbesar-
tan were 5.3 and 5.5 mmol/L respectively.
A double-blind study randomized 1797 patients with 
hypertension (msDBP 95–109 mmHg and 8-hour day-
time ambulatory diastolic BP   90 mmHg) to receive 
once-daily aliskiren 150 mg (n = 437), valsartan 160 mg 
(n = 455), a combination of aliskiren 150 mg and valsar-
tan 160 mg (n = 446), or placebo (n = 459) for 4 weeks, 
followed by force titration to double the dose for another 
4 weeks (Oparil et al 2007). Before the study end, 11% 
of patients discontinued treatment mainly due to lack of 
therapeutic effect. An intention-to-treat analysis at 8- week 
endpoint showed a signiﬁ  cant reduction in msSBP/msDBP 
from baseline with the combination of aliskiren and valsar-
tan when compared to aliskiren (p   0.0001) or valsartan 
(p   0.0001) monotherapy or placebo (p   0.0001) (Table 2). 
ABPM in a subset of patients also showed similar observa-
tion. Both aliskiren and valsartan monotherapy signiﬁ  cantly 
decreased msSBP/msDBP compared to placebo (p   0.0001). 
Combination therapy provide additional reductions of 
4.2/3.2 mmHg over aliskiren monotherapy and 4.4/2.5 mmHg 
over valsartan monotherapy. PRC was highest in the combina-
tion therapy group (912%) compared to patients who received 
aliskiren (468%) or valsartan (138%). While aliskiren 300 mg 
monotherapy and aliskiren/valsartan combination therapy 
decreased PRA (73% and 44% respectively), valsartan 320 mg 
monotherapy increased PRA by 160%. A serum potassium 
of   5.5 mmol/L was observed more frequently during Vascular Health and Risk Management 2008:4(6) 1215
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combination therapy (4%) than during aliskiren or valsartan 
monotherapy (2% each) or with placebo (3%).
The 6-month interim analysis of a long-term, open-label 
study looking at the safety, tolerability and efﬁ  cacy of 
aliskiren/valsartan 300/320-mg combination in patients 
with hypertension (msDBP 90–109 mmHg) was reported 
recently (Chrysant et al 2008). A total of 601 patients 
received aliskiren/valsartan (150/160 mg) combination for 
2 weeks followed by forced titration to aliskiren/valsartan 
300/320 mg once daily for a targeted duration of 52 weeks. 
Optional HCTZ addition was allowed starting from 
week 8 if BP control was inadequate ( 140/90 mmHg). 
At the 6-month point, 512 patients were still ongoing with 
the study and 192 patients received at least once dose of 
HCTZ-add on therapy. Reductions in msSBP/msDBP of 
22.3/14.4 mmHg were observed at 6-month endpoint and 
73.4% of patients achieved BP of   140/90 mmHg. Ten 
patients (2.5%) receiving aliskiren/valsartan and 2 patients 
(1%) receiving aliskiren/valsartan/HCTZ developed serum 
potassium  5.5 mmol/L.
A double-blind multi-center trial, randomized 
837 patients with diabetes mellitus and hypertension 
(msDBP 96–109 mmHg) to once daily aliskiren (150 mg, 
titrated to 300 mg after 4 weeks; n = 282), ramipril 
(5 mg titrated to 10 mg; n = 278) or the combination for 
8 weeks (Uresin et al 2007). When compared to ramipril 
or aliskiren monotherapy, aliskiren/ramipril combination 
provided superior reductions in msDBP (p = 0.004 and 
0.043 respectively) (Table 2). An additional reduction in 
mean BP of 4.6/2.1 mmHg was achieved by the addition 
of aliskiren to ramipril. PRC increased in all groups but 
there was a 66% reduction in PRA from baseline in the 
aliskiren group (p   0.0001) and a 48% reduction in the 
combination group (p   0.0001). The randomized trial 
by Pool et al discussed earlier noted similar reductions in 
msSBP/ msDBP with aliskiren/valsartan 150/160 mg and 
300/320 mg doses when compared to valsartan/HCTZ 
160/12.5 mg dose.
In a double-blind study, 545 patients whose msDBP 
remained at 90–109 mmHg despite 4 weeks of therapy 
with amlodipine 5 mg daily were randomized to 3 arms 
for 6 weeks: continue amlodipine 5 mg, amlodipine 10 mg 
or amlodipine 5 mg with aliskiren 150 mg (Drummond 
et al 2007). At study end, reduction in msSBP/msDBP with 
aliskiren/ amlodipine 150/5 mg was significantly more 
compared to amlodipine 5 mg monotherapy (11.0/8.5 vs 
5.0/4.8 mmHg, p   0.001) but was similar to amlodipine 
10 mg monotherapy (9.6/8.0 mmHg). Peripheral edema 
developed more frequently in the amlodipine 10 mg group 
(11.2%) compared to the combination therapy (2.1%) and 
amlodipine 5 mg (3.4%).
Combination with HCTZ
Antihypertensive efﬁ  cacy of aliskiren has been studied 
both in comparison to and in combination with HCTZ. 
A 12-month randomized study compared the antihyper-
tensive efﬁ  cacy of once-daily doses of aliskiren 300 mg 
and HCTZ 25 mg in1124 patients with mild to moderate 
hypertension (Schmieder et al 2007). Add on therapy with 
amlodipine 5 to 10 mg was used as needed to achieve a 
target BP of 140/90 mmHg. Starting at 12 weeks, aliskiren 
300 mg signiﬁ  cantly lowered BP from baseline compared 
to HCTZ (Table 2).
An 8-week multi-center double-blind trial randomized 
2776 patients with msDBP of 95 to 109 mmHg to differ-
ent doses of aliskiren (75 mg, 150 mg or 300 mg), HCTZ 
(6.25 mg, 12.5 mg or 25 mg), aliskiren/HCTZ combina-
tions (75/6.25, 75/12.5, 75/25, 150/6.25, 150/12.5, 150/25, 
300/12.5, 300/25 mg) or placebo (Villamil et al 2007). 
Aliskiren monotherapy with all 3 doses signiﬁ  cantly lowered 
msDBP compared to placebo with a linear dose relationship 
(p = 0.0002) (Table 2). HCTZ monotherapy with all 3 doses 
also signiﬁ  cantly reduced msDBP compared to placebo but 
with a non-linear dose relationship (p   0.01). All doses of 
HCTZ and aliskiren doses of 150 and 300 mg signiﬁ  cantly 
lowered msSBP compared to placebo. All combinations were 
superior to placebo (p   0.0001) and most were superior to 
both monotherapies (p   0.05) in lowering msDBP (exceptions 
were aliskiren/HCTZ 150/6.25 mg vs either monotherapy and 
aliskiren/HCTZ 75/12.5 mg vs HCTZ monotherapy). Reduc-
tions in msDBP from baseline to endpoint with combination 
therapy ranged from 10.4 ± 0.59 to 14.3 ± 0.61 mmHg. All 
combinations were superior to component monotherapies in 
reducing msSBP from baseline (p   0.05), with the exception 
of aliskiren/HCTZ 75/12.5 mg vs HCTZ monotherapy. Reduc-
tions in msSBP from baseline to end point with combination 
therapy ranged from 14.3 ± 0.93 to 21.2 ± 0.97 mmHg. Great-
est reduction in BP was seen in patients on aliskiren/HCTZ 
300/25 mg (msSBP/ msDBP reduction of 21.5/14.3 mmHg). 
Responder rate (msDBP   90 mmHg and/or  10 mmHg 
reduction from baseline) was 63.9% for aliskiren 300 mg 
(p = 0.0005), 60.6% for HCTZ 12.5 mg (p   0.02), 59.0% 
for HCTZ 25 mg (p   0.02) and 58.4% to 80.6% for all com-
bination doses (all p   0.05) compared to 45.8% for placebo. 
Responder rates for all combinations of aliskiren (75–300 mg) 
with HCTZ 25 mg and aliskiren/HCTZ 300/12.5 mg Vascular Health and Risk Management 2008:4(6) 1216
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were superior to both monotherapies (p   0.05), where as 
aliskiren/HCTZ 75/12.5 mg and 150/12.5 mg were superior 
to their respective aliskiren monotherapies (p   0.05). There 
was a trend towards higher control rare (deﬁ  ned as msSBP/
msDBP   140/90 mmHg at study end) with combination 
therapy (37.4%–59.5%) when compared to either aliskiren 
(29.0%–46.7%) or HCTZ (32.5%–37.7%) monotherapies. 
Among the monotherapy groups, only aliskiren 300 mg 
significantly improved control rate compared to placebo 
(46.7 vs 28.1%, p = 0.0001). Control rate were superior with 
all aliskiren/HCTZ combinations (except 75/6.25 mg group) 
when compared to placebo (p   0.02). The antihypertensive 
effects of aliskiren and HCTZ were comparable but it should 
be noted that the study was powered to compare the antihyper-
tensive effects of the combination therapies with component 
monotherapies but not to compare the monotherapies with each 
other. PRA decreased by 54.2, 65.1 and 57.6% from baseline 
in patients taking aliskiren 75, 150 and 300 mg doses where 
as PRA increased by 3.5, 44.7 and 71.9% with HCTZ doses 
of 6.25, 12.5 and 25 mg. A net reduction in PRA of 46.1% to 
63.5% was observed in patients on aliskiren/HCTZ combina-
tions. Placebo increased PRA only by 0.7% from baseline. PRC 
increased to a greater degree with aliskiren (164, 192 and 348% 
with aliskiren 75, 150 and 300 mg doses) compared to HCTZ 
(10, 26 and 108% with HCTZ 6.25, 12.5 and 25 mg doses). 
The highest PRC increase was seen with aliskiren/HCTZ 
300/25 mg combination (1211% from baseline). Hypokalemia 
(serum potassium  3.5 mmol/L) developed in 3.9% and 5.9% 
of patients on HCTZ 12.5 mg and 25 mg doses respectively. 
The frequency of hypokalemia dropped to 0.7% to 2.0% and 
2.2% to 3.4% respectively with drug combinations containing 
12.5 mg and 25 mg HCTZ.
A 12-month open label study randomized patients 
with msDBP of 90–109 mmHg to aliskiren 150 mg 
(n = 1178) or 300 mg (n = 773) once daily after washout 
and a 2–4 week drug-free period (Sica et al 2006). If BP 
remained  140/90 mmHg after month 2, doubling of aliskiren 
dose from 150 to 300 mg or addition of HCTZ (12.5–25 mg) 
to aliskiren 300 mg was permitted. A subgroup of patients 
remaining on aliskiren monotherapy at month 11 were 
randomized to continue aliskiren (n = 132) or placebo (n = 129) 
for 4 weeks as double-blind withdrawal phase. A total of 1625 
(83%) completed the study. Reductions in msSBP/ msDBP at 
the endpoint were 17.5/12.4 and 18.8/13.3 mmHg in aliski-
ren 150 and 300 mg groups respectively. Addition of HCTZ 
was required in 868 patients (45%) and BP reduction at the 
study end in this group (18.7/12.1 mmHg) was comparable to 
aliskiren monotherapy group (17.4/13.3 mmHg). During the 
withdrawal period, mean sitting BP gradually increased in 
the placebo group where as BP reduction was maintained 
in patients remaining on aliskiren with a statistically signiﬁ  -
cant difference between the groups at the end of withdrawal 
period (5.99/3.87 mmHg p = 0.0001). This difference was 
also seen in a subgroup of patients who underwent ABPM 
(4.14/3.87 mmHg p   0.0001).
The additional antihypertensive beneﬁ  t of aliskiren was 
analyzed in obese hypertensive (msDBP 95–109 mmHg) 
patients unresponsive to 25 mg of HCTZ (Jordan et al 2007). 
After a 2- to 4-week washout period, 560 patients received 
single-blind HCTZ 25 mg for 4 weeks; 490 non-responders 
underwent double-blind randomization to aliskiren 150 mg, 
irbesartan 150 mg, amlodipine 5 mg or placebo for 4 weeks 
while continuing HCTZ. This was followed by doubling 
the initial doses of aliskiren, irbesartan and amlodipine for 
8 weeks. After 8 weeks of double-blind treatment (4 weeks 
on higher doses), BP reduction was signiﬁ  cantly more with 
aliskiren/HCTZ compared to placebo/HCTZ (15.8/11.9 vs 
8.6/7.9 mmHg, p   0.0001) and the signiﬁ  cance persisted at 
study end (p   0.005 for msDBP and p   0.0001 for msSBP). 
BP reductions with irbesartan/HCTZ (15.4/11.3 mmHg) and 
amlodipine/HCTZ (13.6/10.3 mmHg) were similar to aliskiren/
HCTZ (Table 2). The BP control rate (a BP   140/90 mmHg) 
was signiﬁ  cantly higher with aliskiren/HCTZ compared to 
placebo/HCTZ at week 8 end point (p = 0.0005) and at week 
12 end point (58.4% vs 33.3%, p = 0.0001). The BP control 
rate among amlodipine/HCTZ and irbesartan/HCTZ were 
not signiﬁ  cantly different from those observed with aliskiren/
HCTZ at week 8 and 12 end points but the BP control rate with 
aliskiren/HCTZ at week 8 end point was numerically higher 
compared to that observed with amlodipine/HCTZ (56.6 vs 
45.1%, p = 0.052). Compared with pretreatment baseline, 
PRA increased with HCTZ monotherapy (p   0.05) but when 
combined with aliskiren, there was a signiﬁ  cant reduction in 
PRA (p   0.05). Combination of HCTZ with irbesartan and 
amlodipine resulted in further signiﬁ  cant increase in PRA. The 
open-label study by O’Brien et al also looked at the beneﬁ  ts 
of adding 25 mg of HCTZ (n = 23) to 150 mg of aliskiren 
daily for 3 weeks (O’Brien et al 2007). Compared to aliskiren 
monotherapy, there was signiﬁ  cant reduction in day time BP 
with combination therapy (Table 2).
Potential advantages of aliskiren/
HCTZ combination in hypertension
Aliskiren monotherapy in large part demonstrated antihyper-
tensive efﬁ  cacy comparable to equivalent doses of HCTZ, 
losartan, irbesartan, lisinopril and ramipril. Fore effective BP Vascular Health and Risk Management 2008:4(6) 1217
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control, majority of patients will require combination therapy. 
Both ACE inhibitors and ARBs are used extensively in combi-
nation with HCTZ. Aliskiren/HCTZ combination has several 
advantages. HCTZ has been clinically available for decades 
and costs less. It is considered the preferred ﬁ  rst line antihy-
pertensive agent in all comers (Chobanian et al 2003). While 
exerting its antihypertensive effects, HCTZ activates RAAS 
which can limit its efﬁ  cacy. Agents blocking the RAAS such as 
aliskiren, ACE inhibitors and ARBs can augment the potency 
of HCTZ in addition to their own antihypertensive effects. 
At higher doses of aliskiren/HCTZ combination, reduction 
in BP was closer to the sum of BP reductions obtained with 
each monotherapy after excluding the placebo effects from all 
treatment groups. For instance, the placebo-corrected reduction 
in msSBP/ msDBP were 8.2/3.4, 6.9/2.5 and 13.7/7.4 mmHg 
respectively with aliskiren 300 mg, HCTZ 25 mg and aliski-
ren/HCTZ 300/25 mg respectively in a large study (Villamil 
et al 2007). On the other hand, placebo-corrected reductions 
in msSBP/ msDBP with aliskiren 300 mg, valsartan 320 mg 
and aliskiren/valsartan 300/320 mg were 5.0/3.7, 6.5/2.7 and 
8.0/4.3 mmHg respectively in one study (Pool et al 2007) and 
8.4/4.9, 8.2/5.2 and 12.6/ 8.1 mmHg respectively in another 
study (Oparil et al 2007).
In addition to its antihypertensive effects, HCTZ is 
also a week diuretic which helps to correct any underlying 
hypervolemia/sodium excess. Ability of aliskiren to lower 
angiotensin1–7 (Ang1–7) levels may have a potential negative 
impact on BP lowering effects of aliskiren/ACE inhibitor 
and aliskiren/ARB combinations. Ang1–7 is a heptapeptide 
fragment of Ang II that can buffer the vasoconstrictive and 
growth promoting effects of Ang II. Ang1–7 can block AT1 
receptor and stimulate release of nitric oxide and vasodilat-
ing prostaglandins (Dellipizzi et al 1994; Mahon et al 1994; 
Freeman et al 1996; Li et al 1997). Both ACE inhibitors and 
ARBs increase the level of Ang1–7, the former by inhibiting 
the ACE-induced degradation of Ang1–7 and the latter by 
increasing Ang II level (substrate for Ang1–7) through AT1 
receptor blockade. Elevated levels of Ang1–7 are thought to 
be contributing to the antihypertensive effects of both ACE 
inhibitors and ARBs (Luque et al 1996; Iyer et al 1998). 
Since direct renin inhibition can decrease Ang1–7 levels, it is 
intuitive to think that aliskiren might hamper antihypertensive 
effects of both ACE inhibitors and ARBs to some extent.
HCTZ monotherapy can cause hypokalemia and 
combination with aliskiren can mitigate this effect due to 
the potassium retaining effects of the latter. Dual inhibi-
tion of the RAAS can increase the risk of hyperkalemia. 
Fortunately hyperkalemia was not a frequent occurrence in 
studies of aliskiren combination therapy with ACE inhibitors 
and ARBs. The risk will be clearly increased in patients with 
underlying renal dysfunction.
Safety and tolerability
Aliskiren was well tolerated with adverse events and 
discontinuation rates similar to placebo in most clinical 
trials. An increased incidence of diarrhea was reported with 
600 mg dose of aliskiren. The adverse effects of aliskiren 
monotherapy were similar to placebo (39.8% vs 40.2%) in 
a pooled analysis of over 2000 patients (Weir et al 2007). 
Most common adverse effects reported with aliskiren vs 
placebo were head ache (5.75 vs 8.7%), nasopharyngitis 
(4.4% vs 5.8%) and diarrhea (2.6% vs 1.2%). Diarrhea 
was not associated with increased discontinuation rates. 
Serious adverse effects with aliskiren were low at 0.5% 
compared to 0.6% with placebo. Over 95% of the adverse 
effects were mild to moderate in severity thought to be 
unrelated to aliskiren.
Unlike ACE inhibitors, aliskiren does not affect 
the metabolism of bradykinin and substance P. Hence 
cough and angioedema are extremely rare with its use. 
Hyperkalemia is a concern when aliskiren is used in 
combination with ACE inhibitors or ARBs especially 
in patients with impaired renal function. Hypokalemia 
developed in 3.9 and 5.9% of patients who took 12.5 and 
25 mg HCTZ monotherapy which decreased to 0.7%–2.0% 
and 2.2%–3.4% respectively after the addition of aliski-
ren (Villamil et al 2007). Increased adverse effects may 
develop if aliskiren is used in volume depleted patients 
and those with severe renal artery stenosis. Aliskiren is 
contraindicated in pregnancy.
Perspectives on direct renin 
inhibition with aliskiren
RAAS plays a crucial role in chronic hypertension and 
end-organ damage. There is evidence that both ACE 
inhibitors and ARBs lower BP and confer end-organ 
protection in heart, kidney and blood vessels. Their efﬁ  cacy 
is limited by redundant pathways in RAAS and counter regu-
latory mechanisms. Renin has been a therapeutic target for 
long time but a direct renin inhibitor has been available for 
clinical use only recently. Aliskiren may provide more com-
plete and more effective blockade of RAAS. Cathepsin D 
and tonin pathways of Ang I generation are not blocked 
by renin inhibitors. But these pathways are not thought to 
be of signiﬁ  cant physiological importance (Philips et al 
1993). Compared to ACE inhibitors and ARBs, aliskiren Vascular Health and Risk Management 2008:4(6) 1218
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induced more pronounced renal vasodilation in healthy 
normotensive human subjects (Fisher et al 2008). Studies 
thus far have shown similar antihypertensive effects at 
best with aliskiren when compared to equivalent doses 
of ACE- inhibitors, ARBs and diuretics. Aliskiren in 
combination therapies lowered BP more effectively than 
monotherapy and aliskiren/HCTZ combination appear to 
have more synergy. There is evidence from animal studies 
that aliskiren can confer end-organ protection in kidney and 
heart (Pilz et al 2005; Shagdarsuren et al 2005). Animal 
studies have also shown evidence for atherosclerotic 
plaque stabilization with aliskiren (Nussberger et al 2008). 
End organ protective effects of aliskiren in human studies 
are beginning to emerge. The recently published AVOID 
(Aliskiren in eValuation of prOteinuria in Diabetes) study 
has shown reduction in proteinuria independent of BP con-
trol in patients with diabetic nephropathy on background 
therapy with losartan 100 mg/day (Parving et al 2008).
The recently discovered (pro)renin receptor can bind and 
activate both pro-renin and renin with consequent intracel-
lular signaling of second messenger pathways through an 
Ang II independent mechanism. (Pro)renin receptor blockade 
has shown to confer end organ protection in animal studies 
(Takahashi et al 2007). Even though aliskiren could possi-
bly modify pro-renin molecule and prevents its conversion 
to active renin, preliminary evidence indicate that aliskiren 
does not inhibit the renin-induced or pro-renin induced 
activation of the (pro)renin receptor (Schmieder 2007; Schefe 
et al 2008).
The reactive increase in PRC seen with aliskiren is more 
pronounced compared to other antihypertensive agents and is 
dose dependent. PRC increased even further with aliskiren/
HCTZ combination. It was suggested that the elevated PRC 
might be sufﬁ  cient to overwhelm the renin inhibitory capacity 
of aliskiren and may even cause paradoxical elevation of 
BP in patients with hyperreactive RAAS such as those with 
renovascular and malignant hypertension (Sealey and Laragh 
2007). Others have discounted this theory pointing to the 
properties of aliskiren including long half-life and lack of 
rebound hypertension after withdrawal (Menard and Azizi 
2007). Another concern is the possibility that elevated PRC 
might cause harmful effects through the (pro)renin receptor. 
Available evidence indicate that aliskiren does not inhibit 
Ang II-independent intracellular signaling mediated through 
(pro)renin receptor but needs further clariﬁ  cation (Sarris 
et al 2006). Unlike other agents such as ACE inhibitors, 
ARBs and diuretics, aliskiren consistently decreased PRA 
as monotherapy and in combination therapy. Pretreatment 
PRA has shown a direct association with cardiovascular 
risk in hypertensive patients (Aldeman et al 1997). However, 
no study has yet reported such an association with drug 
induced elevations in PRA.
Conclusions
Aliskiren is the ﬁ  rst direct renin inhibitor available for clinical 
use. The long half-life and absence of rebound phenomenon 
makes aliskiren suitable for once daily administration. 
Favorable side-effect profiles and high trough-to peak 
ratios are other features of aliskiren. The antihypertensive 
efﬁ  cacy of monotherapy with aliskiren is dose-dependent 
up to 300 mg daily doses and is comparable to ACE inhibi-
tors such as lisinopril and ramipril, ARBs such as losartan 
and irbesartan as well as HCTZ. Combination therapy with 
ACE inhibitors, ARBs, amlodipine and HCTZ were also 
well tolerated. Because of the complimentary pharmaco-
logical action of aliskiren and HCTZ, their combination 
seems favorable in hypertension. Aliskiren 150 to 300 mg 
with HCTZ 12.5 to 25 mg are the most effective of these 
single daily combinations. Since reactive increase in PRC 
could be a potential limiting factor with aliskiren in terms 
of its antihypertensive efﬁ  cacy and beta blockers can blunt 
this response, combining aliskiren with a beta blocker looks 
attractive. Such a study using aliskiren-atenolol combination 
was completed recently and results are awaited. One has to 
be cautious about the risk of hyperkalemia with strategies 
utilizing dual blockade of RAAS. Studies are underway 
looking at the long-term efﬁ  cacy, safety and tolerability of 
combination therapy of aliskiren with HCTZ or with agents 
blocking RAAS. In addition, outcome studies looking at the 
beneﬁ  cial effects of aliskiren on left ventricular mass in obese 
hypertensive patients as well as its effect on post-myocardial 
infarction LV remodeling are ongoing.
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